Acelyrin Inc (NASDAQ: SLRN) stock fell -0.57% on Friday to $8.79 against a previous-day closing price of $8.84. With 1.09 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.31 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $9.00 whereas the lowest price it dropped to was $8.42. The 52-week range on SLRN shows that it touched its highest point at $29.88 and its lowest point at $7.68 during that stretch. It currently has a 1-year price target of $33.00.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SLRN was up-trending over the past week, with a rise of 9.60%, but this was down by -10.40% over a month. Three-month performance dropped to -67.46% while six-month performance fell -61.38%. For the next quarter, that number is -0.90. This implies an EPS growth rate of 66.23% for this year and 40.75% for next year.

Float and Shares Shorts:

At present, 92.70 million SLRN shares are outstanding with a float of 61.24 million shares on hand for trading. On Oct 30, 2023, short shares totaled 8.23 million, which was 8.46% higher than short shares on Sep 28, 2023. In addition to Dr. Shao-Lee Lin M.D., Ph.D. as the firm’s Co-Founder, CEO & Director, Ms. Melanie Gloria B.S.N. serves as its Chief Operating Officer.

Institutional Ownership:

Through their ownership of 27.32% of SLRN’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 48.32% of SLRN, in contrast to 20.57% held by mutual funds. Shares owned by individuals account for 13.83%. As the largest shareholder in SLRN with 9.60% of the stake, AyurMaya Capital Management Co. L holds 9,334,735 shares worth 9,334,735. A second-largest stockholder of SLRN, Fidelity Management & Research Co, holds 8,961,534 shares, controlling over 9.22% of the firm’s shares. Citadel Advisors LLC is the third largest shareholder in SLRN, holding 5,925,832 shares or 6.09% stake. With a 1.55% stake in SLRN, the SPDR S&P Biotech ETF is the largest stakeholder. A total of 1,505,847 shares are owned by the mutual fund manager. The Vanguard Total Stock Market ETF, which owns about 1.16% of SLRN stock, is the second-largest Mutual Fund holder. It holds 1,131,724 shares valued at 11.53 million. JPMorgan Funds – Global Healthcar holds 1.02% of the stake in SLRN, owning 990,569 shares worth 10.09 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SLRN since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With SLRN analysts setting a high price target of $68.00 and a low target of $15.00, the average target price over the next 12 months is $33.00. Based on these targets, SLRN could surge 673.61% to reach the target high and rise by 70.65% to reach the target low. Reaching the average price target will result in a growth of 275.43% from current levels.

Summary of Insider Activity:

Insiders traded SLRN stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 27 while that of sell transactions has risen to 7 over the past year. The total number of shares bought during that period was 34,368,707 while 3,187,111 shares were sold.

Leave a Reply

Your email address will not be published. Required fields are marked *